BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Increased Reimbursement of Stentys Drug-Eluting Stent in Germany


2/23/2011 11:16:28 AM

PRINCETON, N.J., and PARIS, Feb. 23, 2011 — STENTYS S.A. (STNT.PA)announced today that it has received a higher price reimbursement in Germany for its drug-eluting stent.

“This decision not only fortifies our ongoing commercialization activities in Germany, the largest European market,” said Gonzague Issenmann, CEO and co-founder of STENTYS, “but it is also a clear recognition of the innovation and patient benefit of the STENTYS technology.”

The Institute for the Hospital Remuneration System (InEK) granted this special status of “new and innovative device” (Neue Untersuchungs- und Behandlungsmethoden, or “NUB”) to the STENTYS stent for 2011.

Of note: the STENTYS self-apposing stent represents a major breakthrough compared to conventional stents when treating heart attacks: it “fits snugly” into the contour of a blood vessel and adapts to the anatomic changes of the coronary arteries during the post-AMI phase, eliminating malapposition which exposes patients to serious risk of recurrence of the heart attack.

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its self-apposing stent adapts to the anatomic changes of arteries in the post-infarction phase and thus prevent the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.



Read at BioSpace.com

Stentys
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES